In the AMPLITUDE-O post-hoc analysis, the HR for MACE was 0.70 (95% CI 0.371.30) with baseline SGLT2is and 0.74 (95% CI 0.580.94) without SGLT2is ( P -value for interaction 0.70), and the HR for HHF was 0.23 (95% CI 0.050.97) with SGLT2is and 0.70 (95% CI 0.421.17) without SGLT2is ( P -value for interaction 0.35) [47]
File File history File usage on Commons File usage on other wikis Original file (848 515 pixels, file size: 69 KB, MIME type: image/jpeg) File information Structured data Captions Captions Add a one-line explanation of what this file represents Original upload log [edit] The original description page was here
298 Although diabetic cardiomyopathy was described many years ago, the incidence rates of this disease remain underappreciated
If everything goes as planned, it may be approved by the FDA in 2026 or later
Two hundred and one adolescents with clinical obesity between 12 and 18 were entered in a trial to test the effect of the weight-loss drug semaglutide, marketed under the name Ozempic when it is prescribed for diabetes and Wegovy when prescribed for weight loss
Peptide Vials (GHK-Cu, 50 mg each) A 50 mg vial covers several weeks of dosing, so most courses need only 13 vials
